Title(s):
Assistant Professor of Oncology
Appointment Phone:
410-955-8964
Primary Location:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Expertise:
Esophageal Cancer, Gastroesophageal Cancer, Medical Oncology, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Thymic Carcinoma, Thymoma
Education and Experience
Training
- Royal College of Surgeons in Ireland (Dublin 2 )/ (1998)
Residencies
- Mater Private Hospital (Dublin 7 )/ Internal Medicine (2004)
- Beaumont Hospital (Dublin9 )/ Internal Medicine (2000)
Fellowships
- National Cancer Institute - Oncology (Bethesda MD)/ Medical Oncology (2011)
- Tallaght Hospital / AMNCH (Dublin 24 )/ Medical Oncology (2007)
- Beaumont Hospital (Dublin9 )/ Medical Oncology (2006)
- Waterford Regional Hospital (Waterford )/ Medical Oncology (2005)
Locations
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Baltimore, MD 21231
Phone: 443-287-0005
Appointment Phone: 410-955-8964
Location Map
Department / Division
- Oncology
Centers/Institutes
Centers / Institutes
- Esophageal Cancer Program
- Sidney Kimmel Comprehensive Cancer Center
Bio
Expertise
- Esophageal Cancer
- Gastroesophageal Cancer
- Medical Oncology
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Thymic Carcinoma
- Thymoma
Research
Research and Publications
1. Evaluation of KRAS mutations, angiogenic biomarkers and DCE-MRI in patients with advanced non-small cell lung cancer receiving sorafenib. Kelly RJ, Rajan A, Force J, Keen C, Cao L, Yu Y, Choyke PL, Turkbey B, Raffeld M, Xi L, Steinberg SM, Wright JJ, Lopez-Chavez A, Kummar S, Guttierrez M, Giaccone G. Clin Cancer Res. 2011 Mar 1;17(5):1190-9. Epub 2011 Jan 11
2. A pharmacodynamic study of docetaxel in combination with the p-glycoprotein (Pgp) antagonist, tariquidar (XR9576) in patients with lung, ovarian and cervical cancer. Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE. Clin Cancer Res. 2011 Feb 1;17(3):569-580.
3. A Phase 1 study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor in patients with refractory solid tumor malignancies and lymphomas. Arun Rajan*, Ronan J. Kelly*, Jane B. Trepel, Yeong Sang Kim, Sylvia V. Alarcon, Shivaani Kummar, Martin Gutierrez, Sonja Crandon, Wadih M. Zein, Lokesh Jain, William D. Figg, Brett E.Houk, Michael Shnaidman, Nicoletta Brega, Giuseppe Giaccone. (*co-first authors). Clin Cancer Res. 2011 Nov 1;17(21):6831-9.
4. Thymic Malignancies From Clinical Management To Targeted Development. Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G. J Clin Oncol. 2011 Dec 20, 29(36):4820-7.
5. Belinostat phase II study in patients with recurrent or refractory advanced thymic epithelial tumors. Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, Trepel J, Lee M, Cao L, Espinoza-Delgado I, Spittler J, Loehrer P. J Clin Oncol. 2011 May 20;29(15):2052-9. Epub 2011 Apr 18.
6. A Phase 1 study of the chimeric anti-mesothelin monoclonal antibody MORAB 009 in patients with mesothelin expressing cancers. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. Clin Cancer Res. 2010 Dec 15;16(24):6132-6138.
7. Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab. Kelly RJ, Carter C, Giaccone G. J Clin Oncol. 2010 Oct 1;28(28):e507-10.
8. Targeting the immune system in non small cell lung cancer - bridging the gap between promising concept and therapeutic reality. Kelly RJ, Gulley J, Giaccone G. Clinical Lung Cancer. 2010 Jul 1;11(4):228-37.
9. Chemotherapy and targeted therapy for unresectable malignant mesothelioma. Kelly RJ, Sharon E, Hassan R. Lung Cancer. 2011 Sep; 73(3):256-63. Epub 2011 May 28.
10. The role of Talactoferrin Alfa in non small cell lung cancer. Kelly RJ, Giaccone G. Expert Opin Biol Ther. 2010 Sep;10(9):1379-86.
11. Thymoma associated paraneoplastic polymyositis. Kelly RJ, S Browne, Rajan A, Giaccone G. J Clin Oncol. 2010 Aug 1;28(22):e378.
2. A pharmacodynamic study of docetaxel in combination with the p-glycoprotein (Pgp) antagonist, tariquidar (XR9576) in patients with lung, ovarian and cervical cancer. Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE. Clin Cancer Res. 2011 Feb 1;17(3):569-580.
3. A Phase 1 study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor in patients with refractory solid tumor malignancies and lymphomas. Arun Rajan*, Ronan J. Kelly*, Jane B. Trepel, Yeong Sang Kim, Sylvia V. Alarcon, Shivaani Kummar, Martin Gutierrez, Sonja Crandon, Wadih M. Zein, Lokesh Jain, William D. Figg, Brett E.Houk, Michael Shnaidman, Nicoletta Brega, Giuseppe Giaccone. (*co-first authors). Clin Cancer Res. 2011 Nov 1;17(21):6831-9.
4. Thymic Malignancies From Clinical Management To Targeted Development. Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G. J Clin Oncol. 2011 Dec 20, 29(36):4820-7.
5. Belinostat phase II study in patients with recurrent or refractory advanced thymic epithelial tumors. Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, Trepel J, Lee M, Cao L, Espinoza-Delgado I, Spittler J, Loehrer P. J Clin Oncol. 2011 May 20;29(15):2052-9. Epub 2011 Apr 18.
6. A Phase 1 study of the chimeric anti-mesothelin monoclonal antibody MORAB 009 in patients with mesothelin expressing cancers. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. Clin Cancer Res. 2010 Dec 15;16(24):6132-6138.
7. Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab. Kelly RJ, Carter C, Giaccone G. J Clin Oncol. 2010 Oct 1;28(28):e507-10.
8. Targeting the immune system in non small cell lung cancer - bridging the gap between promising concept and therapeutic reality. Kelly RJ, Gulley J, Giaccone G. Clinical Lung Cancer. 2010 Jul 1;11(4):228-37.
9. Chemotherapy and targeted therapy for unresectable malignant mesothelioma. Kelly RJ, Sharon E, Hassan R. Lung Cancer. 2011 Sep; 73(3):256-63. Epub 2011 May 28.
10. The role of Talactoferrin Alfa in non small cell lung cancer. Kelly RJ, Giaccone G. Expert Opin Biol Ther. 2010 Sep;10(9):1379-86.
11. Thymoma associated paraneoplastic polymyositis. Kelly RJ, S Browne, Rajan A, Giaccone G. J Clin Oncol. 2010 Aug 1;28(22):e378.
More Info
Languages
- English
Additional Resources
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts